BTIG Upgrades AVITA Medical to Buy, Announces $7 Price Target

Benzinga · 1d ago
BTIG analyst Ryan Zimmerman upgrades AVITA Medical (NASDAQ:RCEL) from Neutral to Buy and announces $7 price target.